COVID-19 Versus Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and ATP
Author
Abraham, Edward
Rapaport, Eliezer
Bower, David
Brown, Jack
Griffin, Robert J.
Waitzkin, Ellen D.
Qamar, Kenon
Thompson, Mark A.
Ethirajan, Sukumar
Robinson, Kent
Metadata
Show full item recordCitation
Abraham, Edward, Guido Guidotti, Eliezer Rapaport, David Bower, Jack Brown, et al. 2020. "COVID-19 Versus Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) and ATP." Pre-print.Abstract
We previously published an article in Science discussing the role of ATP in cystic fibrosis (CF). (1) In this manuscript, we update the findings published in that article and add new evidence that the elevated levels of ATP in CF patients may have a protective benefit CF patients infected by SARS-CoV-2 and suffereing from COVID-19. By extension, we suggest a therapeutic regimenthat may benefit COVID-19 in the general populaton.
Terms of Use
This article is made available under the terms and conditions applicable to Other Posted Material, as set forth at http://nrs.harvard.edu/urn-3:HUL.InstRepos:dash.current.terms-of-use#LAACitable link to this page
https://nrs.harvard.edu/URN-3:HUL.INSTREPOS:37374414
Collections
- FAS Scholarly Articles [18296]
Contact administrator regarding this item (to report mistakes or request changes)